Institute of Food, Brain and Behaviour, Beaver House, 23-28 Hythe Bridge Street, Oxford OX1 2EP, UK.
Gencor Pacific Limited, Discovery Bay, Lantau Island, New Territories, Hong Kong, China.
Int J Mol Sci. 2021 May 18;22(10):5305. doi: 10.3390/ijms22105305.
All nations which have undergone a nutrition transition have experienced increased frequency and falling latency of chronic degenerative diseases, which are largely driven by chronic inflammatory stress. Dietary supplementation is a valid strategy to reduce the risk and severity of such disorders. Palmitoylethanolamide (PEA) is an endocannabinoid-like lipid mediator with extensively documented anti-inflammatory, analgesic, antimicrobial, immunomodulatory and neuroprotective effects. It is well tolerated and devoid of side effects in animals and humans. PEA's actions on multiple molecular targets while modulating multiple inflammatory mediators provide therapeutic benefits in many applications, including immunity, brain health, allergy, pain modulation, joint health, sleep and recovery. PEA's poor oral bioavailability, a major obstacle in early research, has been overcome by advanced delivery systems now licensed as food supplements. This review summarizes the functionality of PEA, supporting its use as an important dietary supplement for lifestyle management.
所有经历过营养转型的国家都经历了慢性退行性疾病的发生频率增加和潜伏期下降，而这些疾病在很大程度上是由慢性炎症应激引起的。膳食补充剂是降低此类疾病风险和严重程度的有效策略。棕榈酸乙醇酰胺（PEA）是一种内源性大麻素样脂质介质，具有广泛的抗炎、镇痛、抗菌、免疫调节和神经保护作用。它在动物和人类中具有良好的耐受性，并且没有副作用。PEA 通过调节多种炎症介质对多种分子靶点的作用，在许多应用中提供治疗益处，包括免疫、大脑健康、过敏、疼痛调节、关节健康、睡眠和恢复。PEA 的口服生物利用度较差，这是早期研究中的一个主要障碍，现已通过先进的输送系统克服，这些系统现已获得食品补充剂的许可。这篇综述总结了 PEA 的功能，支持其作为生活方式管理的重要膳食补充剂的使用。
